Companies developing competing Hepatitis C treatments, including Vertex (VRTX), Achillion (ACHN) and Idenix (IDIX), are trading higher pre-market after Gilead (GILD) reported this morning that the majority of hepatitis C genotype 1 patients in its ongoing ELECTRON study experienced viral relapse within four weeks.
European stocks rose for a third straight session on Monday and the euro bounced back from two-year lows, as Greek …
There are no comments yet